Eli Lilly's revenue rises 5 percent as diabetes drugs gain
Advertisement
Drugmaker Eli Lilly and Co reported a 5 percent rise in quarterly revenue, helped by increased sales of its diabetes drugs and higher volume.
The company in early January said its Jardiance diabetes treatment grabbed market share during the fourth quarter but forecast 2016 revenue below expectations.
Net income rose to $478.4 million, or 45 cents per share, in the fourth quarter ended Dec. 31, from $428.5 million, or 40 cents per share, a year earlier.
Excluding special items, the company earned 78 cents per share, in line with the average analyst expectation, according to Thomson Reuters I/B/E/S.
Revenue rose to $5.38 billion from $5.12 billion. Analysts on average had expected $5.32 billion.
The company in early January said its Jardiance diabetes treatment grabbed market share during the fourth quarter but forecast 2016 revenue below expectations.
Net income rose to $478.4 million, or 45 cents per share, in the fourth quarter ended Dec. 31, from $428.5 million, or 40 cents per share, a year earlier.
Excluding special items, the company earned 78 cents per share, in line with the average analyst expectation, according to Thomson Reuters I/B/E/S.
Revenue rose to $5.38 billion from $5.12 billion. Analysts on average had expected $5.32 billion.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.